Collins Liu, MD
Behavioral Neurology & Neuropsychiatry · San Diego, CANPI 1851547459
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $28,861 of the $37,438 with a category attached, or 77.1%. 33 manufacturers reported payments, led by Eisai Inc. at 40.8% of the total. Reporting peaked in 2023 at $17,521 and has fallen 99.1% since, to $153 in 2025.
Across 199 payments — averaging $188.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$15K
- Biogen$10K
- Eli Lilly$9K
- Lilly USA, LLC$600
- AbbVie$574
- Teva Pharmaceuticals USA, Inc.$447
- plus $2K from 27 others
Across 23 payments — averaging $38,996 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$897K
What the payments were for
- Consulting fees$28,86177%
- Speaking & faculty fees$1,6955%
- Travel & lodging$2,5337%
- Food & beverage$4,35012%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 16 | $15,290 |
| Biogen | 9 | $9,708 |
| Eli Lilly | 6 | $8,551 |
| Lilly USA, LLC | 22 | $600 |
| AbbVie(2 entities) | 27 | $574 |
| Teva Pharmaceuticals USA, Inc. | 9 | $447 |
| Abbott | 2 | $284 |
| Amgen | 14 | $263 |
| Johnson & Johnson | 5 | $208 |
| Zyla Life Sciences, Inc. | 26 | $182 |
| Impel Pharmaceuticals Inc. | 2 | $167 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $159 |
| Lundbeck LLC | 5 | $116 |
| Upsher-smith Laboratories LLC | 5 | $104 |
| Novartis | 6 | $99 |
| Biohaven Pharmaceuticals, Inc. | 4 | $91 |
| Vanda Pharmaceuticals Inc. | 5 | $90 |
| Otsuka America Pharmaceutical, Inc. | 4 | $83 |
| UCB, Inc. | 2 | $59 |
| Acadia Pharmaceuticals Inc | 3 | $47 |
| Pfizer | 2 | $46 |
| Avanir Pharmaceuticals, Inc. | 2 | $36 |
| CSL Behring | 2 | $35 |
| Neurocrine Biosciences, Inc. | 2 | $32 |
| Kyowa Kirin, Inc. | 2 | $29 |
| Scilex Pharmaceuticals Inc. | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Merz North America, Inc. | 1 | $18 |
| Almatica Pharma LLC | 1 | $17 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
| Sanofi | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Leqembi$12,156
- ADUHELM$1,695
- AUSTEDO$243
- Confirm Rx$180
- BOTOX$156
- EMGALITY$125
- AJOVY$118
- Trudhesa$104
- Quadra Assura CRT Defibrillator$103
- SPRAVATO$101
How this compares
Too few behavioral neurology & neuropsychiatry providers in Californiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 19 | $29,407 |
| QuliptaAtogepant | 12 | $15,702 |
| RivastigmineRivastigmine Tartrate | 85 | $4,309 |
| Rivastigmine | 17 | $4,011 |
| Memantine Hcl ErMemantine Hcl | 11 | $1,903 |
| Memantine Hcl | 73 | $1,793 |
| Donepezil Hcl | 158 | $1,323 |
| Levetiracetam | 20 | $748 |
| Oxcarbazepine | 12 | $642 |
| Escitalopram Oxalate | 41 | $558 |
| Quetiapine Fumarate | 29 | $474 |
| Gabapentin | 65 | $463 |
| Trazodone Hcl | 76 | $400 |
| Galantamine Hbr | 11 | $356 |
| Duloxetine Hcl | 14 | $239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $46 | $29,40719 claims |
| AbbVieQulipta | $574 | $15,70212 claims |
| Almatica Pharma LLCSertraline Hcl | $17 | $3314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few behavioral neurology & neuropsychiatry providers in Californiaon file to place this against a meaningful peer group, so we don't.
Other behavioral neurology & neuropsychiatry in San Diego
- Gabriel LegerSan Diego$4K
- Anish DhamijaSan Diego$57
- Nihal DesilvaSan Diego$32
- Seyed SajjadiOrange$10K
- Neda HeidariOxnard$8K
- Sharon ShaStanford$8K
- Michael FrazierWestminster$8K
- Paramjit SinghChico$4K
- Peter WagnerRancho Mirage$666
- Balasubramaniam GulasekaramCerritos$310
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.